Anebulo Pharmaceuticals, Inc. (ANEB)
Nasdaq · Healthcare · Biotechnology
$0.260.00%as of Nov 5, 2026, 7:50 AM ET
- Market cap
- $10.6M
- 52-week range
- $0.001 – $2.51
- 52-week change
- −89.60%
- EPS (trailing)
- −$0.19
Fiscal year to Jun 2025
- Net income
- −$8.5M
- Diluted EPS
- −$0.25
From the company’s annual report on SEC EDGAR.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Headquarters: Lakeway, United States · 2 employees · anebulo.com